

ESMO Preceptorship Programme Colorectal Cancer

Multidisciplinary management, standards of care and future perspectives
March 27-28th 2015, SINGAPORE

FACULTY

CO-CHAIRS: Jean-Yves Douillard, France Claus-Henning Köhne, Germany	SPEAKERS: Daniela Aust, Germany Michel Ducreux, France Hauke Lang, Germany Kong Hwai Loong, SG Mark Saunders, United Kingdom Francis Seow-Choen, Singapore
---	--

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments, and in special situations

Friday, 27th March 2015

09:00-9:15	Welcome and introduction	JY Douillard, FR Francis Seow-Choen, SG
------------	--------------------------	--

09:15 -10:50 95'	Session 1 Early colorectal cancer	Chair: C H Koehne, DE
30'	The point of view of the pathologist - Quality and rules of a good pathology report - Histoprognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Daniela Aust, DE
20'	State-of-the-art: Standard of surgical practice for resectable colorectal cancer (special issues on rectal cancer)	Francis Seow-Choen, SG
30'	State-of-the-art: Standard(s) of perioperative radio/chemotherapy for rectal cancer	Mark Saunders, UK
15'	Discussion	Faculty

10:50-11:10	Coffee Break
-------------	--------------

11:10-13:00 105'	Session 2 Adjuvant settings of colorectal cancer	Chair: JY Douillard, FR
30'	Microsatellite instability: Where do we stand? How useful is it?	Daniela Aust, DE
30'	Adjuvant treatment for colon cancer III	Kong Hwai Loong, SG
30'	Adjuvant treatment of stage II Which patients to treat?	CH Koehne
20'	Discussion	Faculty

13:00-14:00 60'	LUNCH	
--------------------	-------	--

14:00-14:30 30'	Session 3 Clinical cases	Chair: CH Koehne, DE JY Douillard, FR
30'	2 Clinical cases from participants (10'/case + 5'discussion)	Faculty

14:30-16:15 105'	Session 4: Metastatic colorectal cancer, liver limited metastases	Chair: Francis Seow-Choen, SG
15'	Review of the ESMO consensus conference on metastatic colorectal cancer - Basic strategies and groups (RASwt /mut, BRAF mut)	Jean-Yves Douillard, FR
15'	Development of conventional chemotherapy in mCRC, BSC vs, Chemo, biochemical modulation, oral fluoropyrimidines, development of combination chemotherapy	CH Koehne
30'	Resection of liver limited metastasis (Resectable cases, Group 0) - Upfront - After neo-adjuvant treatment - Repeated hepatectomy	Hauke Lang, DE
30'	Unresectable or borderline resectable (Group 1) chemotherapy +/- targeted agents	CH Koehne, DE
15'	Discussion	Faculty

16:15-16:45	Coffee Break
-------------	--------------

16:45-18:30 105'	Session 5 Special clinical situations: Mono- or oligometastatic disease	Chair: CH Koehne, DE
---------------------	--	----------------------

30'	Treatment of metastatic disease confined to the peritoneum <ul style="list-style-type: none"> - Resection - HIPEC - PIPEC 	Hauke Lang, DE
30'	Options of locoregional treatment of liver metastasis <ul style="list-style-type: none"> - intraarterial therapy - chemoembolisation - SIRT - Local radiation 	M Ducreux FR
30'	Primary with synchronous metastases	Hauke Lang, DE
15'	Discussion	Faculty

Time TBC	Dinner
----------	--------

Saturday, 28 March 2015

09:00-10:30 90'	Session 6 Metastatic colorectal cancer I	Chair: CH Koehne, DE
25'	The role of EGFR inhibition in mCRC	Jean-Yves Douillard, FR
25'	The role of VEGF inhibition in mCRC	CH Koehne, DE
10'	Discussion	Faculty
25'	The role of maintenance, appropriate endpoints according to ESMO consensus	M Ducreux FR
5'	Discussion	Faculty

10:30-11:00	Coffee Break
-------------	--------------

11:00-12:15 75'	Session 7 Metastatic colorectal cancer II	Chair: M Ducreux, FR
30'	<ul style="list-style-type: none"> - The Continuum of Care in colorectal cancer versus lines of treatment - Appropriate use of new agents (afibercept and regorafenib) within the treatment algorithm - Re-introduction of regimens? 	Jean-Yves Douillard, FR
30'	Management of treatment related side effects <ul style="list-style-type: none"> - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension Hand-foot syndrome 	M Ducreux
15'	Discussion	Faculty

12:15-13:00 45'	Session 8 Case presentations from participants followed by panel discussion	Chair: CH Koehne, DE JY Douillard, FR
3X15'	3 Clinical cases from participants (10'/case + 5'discussion)	Faculty

13:00-13:15 15'	Conclusion and farewell	Chair: CH Koehne, DE JY Douillard, FR
13:15-14:00	LUNCH	